Hydroxyzine

Verify with FDA CVM →

982 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
982
Total Reports
38
Deaths Reported
390.0%
Death Rate

Active Ingredients

Hydroxyzine

Administration Routes

OralUnknownOphthalmic

Species Affected

Dog 950
Cat 15
Human 9
Unknown 5
Horse 3

Most Affected Breeds

Retriever - Labrador 94
Shih Tzu 51
Crossbred Canine/dog 49
Terrier - Yorkshire 44
Retriever - Golden 37
Boxer (German Boxer) 32
Terrier - West Highland White 31
Terrier (unspecified) 29
Shepherd Dog - German 28
Chihuahua 28

Most Reported Reactions

Emesis 213
Vomiting 166
Lethargy (see also Central nervous system depression in 'Neurological') 127
Diarrhoea 81
Other abnormal test result NOS 75
Lack of efficacy - NOS 74
Elevated serum alkaline phosphatase (SAP) 46
Elevated alanine aminotransferase (ALT) 42
Seizure NOS 41
Anorexia 41
Behavioural disorder NOS 41
Decreased appetite 37

Outcome Breakdown

Recovered/Normal
423 (43.3%)
Ongoing
309 (31.6%)
Outcome Unknown
170 (17.4%)
Recovered with Sequela
37 (3.8%)
Euthanized
20 (2.0%)
Died
18 (1.8%)

Data Summary

Metric Value
Total adverse event reports 982
Reports involving death 38
Case-fatality rate (reported events) 390.0%
Distinct species in reports 5
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Hydroxyzine Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 982 adverse event reports referencing Hydroxyzine, including 38 reports in which the animal died — a 390.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Hydroxyzine. Reported administration routes include Oral, Unknown, Ophthalmic. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Hydroxyzine reports are Dog (950 reports), Cat (15 reports), Human (9 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (94), Shih Tzu (51), Crossbred Canine/dog (49) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Hydroxyzine are Emesis (213), Vomiting (166), Lethargy (see also Central nervous system depression in 'Neurological') (127), Diarrhoea (81). Of the 977 reports with a coded outcome, Recovered/Normal is the leading category at 43.3%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Hydroxyzine.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial